GP KFPs / SAQs · cardiovascular-health
Atrial fibrillation — KFP-style written assessment
KFP-style staged scenarios on atrial fibrillation: new AF workup and anticoagulation thresholds, DOAC dosing to criteria, rate versus early rhythm control with the trial evidence, cardioversion rules, and the elderly patient everyone under-anticoagulates.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
Atrial fibrillation: score it, anticoagulate it, control the rate, and time the rhythm
KFP 1 (10 marks)
A 72-year-old male teacher presents after two days of palpitations. ECG confirms atrial fibrillation at 118 beats per minute; blood pressure 138/84. He has treated hypertension and type 2 diabetes, walks daily, drinks four standard beers most nights, and his TSH is pending. [4]
- Calculate his CHA2DS2-VASc score and state the anticoagulation recommendation with the treatment thresholds. (3) [4]
- His wife read that "blood thinners cause bleeds". How do you use a HAS-BLED assessment correctly in this conversation? (3) [5]
- Which DOAC will you start and at what dose? Give the trial evidence that supports the class choice over warfarin and over aspirin. (4) [8][1]
Model answers
- Hypertension (1) + diabetes (1) + age 65–74 (1) = 3. Oral anticoagulation is recommended for men at 2 or more and women at 3 or more, considered at 1 and 2 respectively — he is clearly above threshold. The score's value lies in its low-risk floor: in derivation, low-score patients recorded no thromboembolic events at all. [4]
- HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly above 65, Drugs/alcohol) quantifies one-year major-bleeding risk and surfaces modifiable factors — his alcohol and blood pressure are both fixable. It informs monitoring intensity and counselling; it never overrides a stroke indication. Frame it as "we reduce what we can reduce, and we still protect you from stroke". [5]
- Apixaban 5 mg twice daily (no dose-reduction criteria met). Class evidence: ARISTOTLE — apixaban superior to warfarin for stroke/systemic embolism (HR 0.79), less major bleeding (HR 0.69), lower mortality (HR 0.89); RE-LY and ROCKET-AF corroborate across agents; COMBINE AF patient-level meta-analysis confirms standard-dose DOACs safer and more effective than warfarin down to CrCl 25 mL/min, while reduced doses raise stroke and death without cutting bleeding. Aspirin has no role: BAFTA showed warfarin halved primary events versus aspirin even in the elderly. Also address his alcohol — each extra drink/day adds about 6% relative AF risk. [1][8][2]
References8ShowHide
- [1]Granger CB et al. Apixaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 2011.PMID 21870978
- [2]Mant J et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet (London, England), 2007.PMID 17693178
- [3]Van Gelder IC et al. Lenient versus strict rate control in patients with atrial fibrillation. The New England journal of medicine, 2010.PMID 20231232
- [4]Lip GY et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest, 2010.PMID 19762550
- [5]Pisters R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest, 2010.PMID 20299623
- [6]Kirchhof P et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. The New England journal of medicine, 2020.PMID 32865375
- [7]Wyse DG et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. The New England journal of medicine, 2002.PMID 12466506
- [8]Harrington J et al. Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF. Circulation, 2023.PMID 37042255